阿那曲普长期安全性与有效性:REVEAL试验延长期随访
REVEAL试验纳入30 449例动脉粥样硬化性血管病患者,在开放标签阿托伐他汀基础上随机加用阿那曲普100 mg/日或安慰剂。治疗期(中位4.1年)主要冠脉事件降低9%,延长期随访(中位2.2年)进一步降低20%,总随访(中位6.3年)降低12%(绝对降低1.8%),未发现非血管死亡或癌症等严重不良事件增加。
要点
- 阿那曲普治疗期主要冠脉事件降低9%,延长期随访进一步降低20%。
- 总随访中位6.3年主要冠脉事件降低12%,绝对降低1.8%。
- 未发现非血管死亡、特定部位癌症或其他严重不良事件显著增加。
核心结论
- 阿那曲普对主要冠脉事件的获益随随访时间延长而增加,且未出现非血管死亡或 morbidity 的不良影响。
研究设计与样本
- REVEAL为随机对照试验,纳入30 449例既往动脉粥样硬化性血管病成人,随机分配阿那曲普100 mg每日或安慰剂,均加用开放标签阿托伐他汀。
- 停止随机治疗后26 129例存活者进入盲态延长期随访,主要终点为随机化后首次主要冠脉事件,按意向性治疗分析。
主要发现
- 治疗期(中位4.1年)主要冠脉事件比例降低9%(95%CI 3-15%,P=0.004)。
- 延长期随访(中位2.2年)主要冠脉事件进一步降低20%(95%CI 10-29%,P<0.001)。
- 总随访(中位6.3年)主要冠脉事件降低12%(95%CI 7-17%,P<0.001),绝对降低1.8%(95%CI 1.0-2.6%)。
- 非血管死亡、特定部位癌症或其他严重不良事件无显著影响;25 784例(99%)获得 morbidity 随访。
临床怎么用
- 对于接受强化他汀治疗的动脉粥样硬化性血管病患者,加用阿那曲普的冠脉事件获益需足够长的治疗和随访时间才能充分显现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: REVEAL was the first randomized controlled trial to demonstrate that adding cholesteryl ester transfer protein inhibitor therapy to intensive statin therapy reduced the risk of major coronary events. We now report results from extended follow-up beyond the scheduled study treatment period. METHODS AND RESULTS: A total of 30 449 adults with prior atherosclerotic vascular disease were randomly allocated to anacetrapib 100 mg daily or matching placebo, in addition to open-label atorvastatin therapy. After stopping the randomly allocated treatment, 26 129 survivors entered a post-trial follow-up period, blind to their original treatment allocation. The primary outcome was first post-randomization major coronary event (i.e. coronary death, myocardial infarction, or coronary revascularization) during the in-trial and post-trial treatment periods, with analysis by intention-to-treat. Allocation to anacetrapib conferred a 9% [95% confidence interval (CI) 3-15%; P = 0.004] proportional reduction in the incidence of major coronary events during the study treatment period (median 4.1 years). During extended follow-up (median 2.2 years), there was a further 20% (95% CI 10-29%; P < 0.001) reduction. Overall, there was a 12% (95% CI 7-17%, P < 0.001) proportional reduction in major coronary events during the overall follow-up period (median 6.3 years), corresponding to a 1.8% (95% CI 1.0-2.6%) absolute reduction. There were no significant effects on non-vascular mortality, site-specific cancer, or other serious adverse events. Morbidity follow-up was obtained for 25 784 (99%) participants. CONCLUSION: The beneficial effects of anacetrapib on major coronary events increased with longer follow-up, and no adverse effects emerged on non-vascular mortality or morbidity. These findings illustrate the importance of sufficiently long treatment and follow-up duration in randomized trials of lipid-modifying agents to assess their full benefits and potential harms. TRIAL REGISTRATION: International Standard Randomized Controlled Trial Number (ISRCTN) 48678192; ClinicalTrials.gov No. NCT01252953; EudraCT No. 2010-023467-18.
引用
- Sammons E, Hopewell JC, Chen F, et al. Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. Eur Heart J. 2022. PMID: 34910136. doi:10.1093/eurheartj/ehab863
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。